- Home
- EPC vs AVDL Comparison
EPC vs AVDL Comparison
Compare EPC & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPC
- AVDL
- Stock Information
- Founded
- EPC 1999
- AVDL 2015
- Country
- EPC United States
- AVDL Ireland
- Employees
- EPC N/A
- AVDL N/A
- Industry
- EPC Package Goods/Cosmetics
- AVDL Biotechnology: Pharmaceutical Preparations
- Sector
- EPC Consumer Discretionary
- AVDL Health Care
- Exchange
- EPC Nasdaq
- AVDL Nasdaq
- Market Cap
- EPC 1.4B
- AVDL 1.5B
- IPO Year
- EPC 2000
- AVDL 1996
- Fundamental
- Price
- EPC $19.72
- AVDL $18.57
- Analyst Decision
- EPC Buy
- AVDL Buy
- Analyst Count
- EPC 6
- AVDL 10
- Target Price
- EPC $26.33
- AVDL $18.94
- AVG Volume (30 Days)
- EPC 542.6K
- AVDL 4.3M
- Earning Date
- EPC 11-13-2025
- AVDL 11-11-2025
- Dividend Yield
- EPC 3.05%
- AVDL N/A
- EPS Growth
- EPC N/A
- AVDL N/A
- EPS
- EPC 1.34
- AVDL N/A
- Revenue
- EPC $2,203,900,000.00
- AVDL $221,075,000.00
- Revenue This Year
- EPC N/A
- AVDL $64.21
- Revenue Next Year
- EPC $2.18
- AVDL $30.80
- P/E Ratio
- EPC $14.69
- AVDL N/A
- Revenue Growth
- EPC N/A
- AVDL 132.35
- 52 Week Low
- EPC $19.13
- AVDL $6.38
- 52 Week High
- EPC $38.45
- AVDL $18.65
- Technical
- Relative Strength Index (RSI)
- EPC 39.17
- AVDL 79.97
- Support Level
- EPC $19.50
- AVDL $13.83
- Resistance Level
- EPC $20.30
- AVDL $18.65
- Average True Range (ATR)
- EPC 0.50
- AVDL 0.59
- MACD
- EPC 0.08
- AVDL 0.43
- Stochastic Oscillator
- EPC 23.17
- AVDL 97.93
About EPC Edgewell Personal Care Company
Edgewell Personal Care Co is a personal-care company. The operating segments of the company include Wet Shave, Sun and Skin Care and Feminine Care. Some of the brands offered by the company include Edge, Skintimate, Personna, Schick, Carefree, Playtex, Banana Boat and Hawaiian Tropic. It derives a majority of its revenue from the United States.
About AVDL Avadel Pharmaceuticals plc
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.